AbD Serotec Secures Exclusive Worldwide Manufacturing License to Key Research Antibodies from VU University Medical Center
(Thomson Reuters ONE) -
MorphoSys AG / AbD Serotec Secures Exclusive Worldwide Manufacturing License to Key Research Antibodies from VU University Medical Center processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement.
Deal Strengthens AbD Serotec's Position as Primary Source of Reagents for
Studying the Innate Immune System
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that its
research and diagnostic antibodies unit AbD Serotec has signed a license
agreement with VU University Medical Center (VUmc), which provides AbD Serotec
with worldwide exclusive rights to commercialize a number of antibody clones for
research applications. These include the world's most widely used reagents for
studying macrophage subsets in rats, the "ED series" of antibodies.
The antibodies are key reagents for studying various cell types and processes
which play a central role in the innate immune system. The innate immune system
forms an initial line of defense against diverse invading foreign pathogens and
damaged or infected host cells. It acts through a variety of primitive and more
advanced mechanisms, including the complement cascade, pattern recognition
receptors, and macrophages to identify and target foreign intruders. In
addition, it initiates the host's adaptive immune response via antigen
presentation by dendritic cells. The original paper on the ED antibodies is a
key publication in the field being cited over 1,600 times.
"In line with our strategy to achieve a market-leading position in key focus
areas, we have decided to further expand our offering in innate immunity
research and take an exclusive manufacturing license for a range of ED antibody
clones from the VU University Medical Center," commented Dieter Feger, Head of
AbD Serotec. "AbD Serotec already provides an extensive collection of antibodies
for studying the activities and actions of the innate immune system, all
manufactured to highest quality standards and guaranteed for use in important
applications such as flow cytometry and western blotting."
AbD Serotec has launched a new website area summarizing its offering of
performance-guaranteed antibodies and reagents focused on macrophages and
dendritic cells, toll-like receptors, pattern recognition receptors, natural
killer cell markers, and the complement cascade. For further information, visit
www.abdserotec.com
About MorphoSys:
MorphoSys is an independent biotechnology company that develops novel antibodies
for therapeutic, diagnostic and research applications. The Company's HuCAL
technology is one of the most powerful methods available for generating fully
human antibodies. By successfully applying this and other proprietary
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human health-care.
Through its alliances with some of the world's leading pharmaceutical companies,
MorphoSys has created a pipeline of more than 60 drug candidates. The Company is
expanding its drug pipeline by adding new partnered programs, and by building a
portfolio of fully-owned therapeutic antibodies. For its proprietary portfolio,
the Company is focused on the areas of oncology and inflammation. Its most
advanced program MOR103, a first-in-class, fully human antibody against GM-CSF,
is currently tested in a Phase Ib/IIa trial in rheumatoid arthritis patients.
Via its business unit AbD Serotec, MorphoSys is expanding the reach of its
technologies in the diagnostics and research markets. MorphoSys is headquartered
in Munich, Germany and listed on the Frankfurt Stock Exchange under the symbol
"MOR". For further information, visithttp://www.morphosys.com/
HuCAL(®), HuCAL GOLD(®), HuCAL PLATINUM(®), CysDisplay(®) and RapMAT(®) are
registered trademarks of MorphoSys AG.
About VU University Medical Center:
VU University Medical Center's core business consists of patient care,
scientific research, and education. Its focal areas in care and research are:
cancer and the immune system, the brain, movement, vital functions and
extramural care. Every year, 38,000 patients are admitted (some for day
therapy), over 300,000 patients visit the outpatient clinic and 40,000 visit the
Emergency Department. About 2,000 medical students receive an education. The
results of scientific research are presented in about 2,000 scientific
publications and reports each year, including about 100 PhD theses.
This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.
For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122
Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454
Jessica Kulpi
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332
investors(at)morphosys.com
[HUG#1444625]
--- End of Message ---
MorphoSys AG
Lena-Christ-Str. 48 Martinsried / München Germany
WKN: 663200;ISIN: DE0006632003;Index:TecDAX,Prime All Share,CDAX,TECH All Share,HDAX,MIDCAP;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
Press Release (PDF):
http://hugin.info/130295/R/1444625/388239.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE
Unternehmensinformation / Kurzprofil:
Datum: 16.09.2010 - 07:30 Uhr
Sprache: Deutsch
News-ID 42598
Anzahl Zeichen: 0
contact information:
Town:
Martinsried / München
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 234 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"AbD Serotec Secures Exclusive Worldwide Manufacturing License to Key Research Antibodies from VU University Medical Center"
steht unter der journalistisch-redaktionellen Verantwortung von
MorphoSys AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
